GMP Expectations for Products Used in Early Phase IND Studies
Instructor:
Steven S Kuwahara
Product ID: 701009
- Duration: 75 Min
FDA has issued a guidance document covering GMP requirements for products that will be used in early stage clinical studies. These guidelines are in addition to those that cover the CMC sections for IND submissions at Phase 1. The nature and extent of the GMP activities depend upon the nature of the investigational drug and the extent of the study that is planned. This presentation will review the GMP guidance document and discuss how it may be integrated with the recommendations of the guidance documents on CMC requirements.
Areas Covered in the seminar:
- Discussion of the elements to be found in the key guidance document for Phase 1 material.
- What to do at really early stages.
- What about special IND studies?
- What about preclinical studies?
- Varying GMP activities that depend upon the nature of the IND product.
- Which regulations come into play at different stages of product development.
- What to do about QC activities such as instrument qualification, method validation, and process validation.
Who will benefit:
This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany early stages of Product development.
- Regulatory Affairs personnel who coordinate activities for the CMC sections of submissions
- QA/QC personnel who need to plan work
- R & D personnel who will contribute data to CMC sections
- Project managers for product development studies
- Quality systems auditors
- Consultants
Steven S. Kuwahara, Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . He has participated in the product development process for small molecule drugs and biologics, and has prepared or reviewed many CMC sections.
More Training By Experts
- Auditing Analytical Laboratories for FDA Compliance
- Monoclonal Antibodies and Therapeutic Proteins: Designing GLP Compliant Nonclinical Programs to Meet FDA Expectations
- Differences in GMP Requirements between Drugs and Biologicals
- Quality Expectations for Product Development CMC Activities: R & D, GLP or GMP
- Small GMP problems which cause the biggest enforcement headaches: how to tackle them
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
